CUDC 305

12/01/2009 - "In a combination study, CUDC-305 enhanced the antitumor activity of a standard-of-care agent in the H1975 tumor model. "
12/01/2009 - "In addition, CUDC-305 significantly prolongs animal survival in orthotopic lung tumor models of H1975 and A549, which may be partially attributed to its preferential exposure in lung tissue. "
06/15/2009 - "CUDC-305 is a promising drug candidate for the treatment of a variety of cancers, including brain malignancies."
06/15/2009 - "CUDC-305 exhibits high oral bioavailability (96.0%) and selective retention in tumor (half-life, 20.4 hours) compared with normal tissues. "
06/15/2009 - "CUDC-305 shows high affinity for HSP90alpha/beta (IC(50), approximately 100 nmol/L) and HSP90 complex derived from cancer cells (IC(50), 48.8 nmol/L). "

06/15/2009 - "In combination studies, CUDC-305 enhances the antitumor activity of standard-of-care agents in breast and colorectal tumor models. "

11/01/2014 - "The objective of the present study was to explore the ability of Debio 0932 to alleviate psoriasis in a preclinical model. "
11/01/2014 - "Debio 0932 was administered perorally daily for 3 weeks and resulted in significant clinical alleviation of psoriasis by day 11 and reduced epidermal thickness evaluated post-treatment. "
11/01/2014 - "Alleviation of psoriasis in the psoriasis xenograft transplantation model, which may be due to Hsp90's involvement in signalling pathways that are up-regulated in psoriasis, substantiates a potential role of Debio 0932 in psoriasis treatment. "
11/01/2014 - "Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model."

12/01/2009 - "Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer."
06/15/2009 - "CUDC-305 also displays potent antitumor activity in animal models of erlotinib-resistant non-small cell lung cancer and induces tumor regression in animal models of MDA-MB-468 breast cancer and MV4-11 acute myelogenous leukemia. "

06/15/2009 - "CUDC-305 also displays potent antitumor activity in animal models of erlotinib-resistant non-small cell lung cancer and induces tumor regression in animal models of MDA-MB-468 breast cancer and MV4-11 acute myelogenous leukemia. "